TMCnet News
OncLive® Presents State of the Science Summit™: Hematologic MalignanciesOncLive®, a leading digital provider of resources and information for oncology professionals, presents the latest State of the Science Summit™ on Hematologic Malignancies at the W Hotel San Francisco on Dec. 16 from 9:00 a.m. to 1:00 p.m. The summit will follow the Annual Meeting and Exposition in Atlanta, Georgia, which is being held Dec. 9-12. The program will be chaired by Thomas G. Martin, M.D., clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, UCSF; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center. The summit will serve as a networking platform for attending professionals, and will provide an overview of the updates on the field of Hematology. The following expert faculty speakers from the University of California San Francisco (UCSF) will share their expertise on topics including treatment of newly diagnosed multiple myeloma, immunotherapy and novel agents for refractory multiple myeloma, novel therapies for acute myeloid leukemia, follicular and mantle cell lymphomas and CAR T-cell therapy for non-hodgkin lymphoma:
Registration is free and open to all health care professionals. For more information and to register, visit www.onclive.com/meetings/soss or contact Allison Cooper at [email protected]. About OncLive® A digital platform of resources for practicing oncologists, OncLive.com offers oncology professionals information they can use to help provide the best patient care. OncLive® is the official website for Michael J. Hennessy Associates' Oncology Specialty Group, which publishes OncologyLive®, Oncology Nursing News®, Oncology Business Management™ and more. Michael J. Hennessy Associates Inc. is a full-service health care communications company offering education, research and medical media, including curetoday.com and CURE® magazine, the largest U.S. consumer publication focused entirely on cancer. Combining science and humanity to make cancer understandable, CURE® reaches patients, cancer centers and advocacy groups. View source version on businesswire.com: http://www.businesswire.com/news/home/20171205006139/en/ |